Form D · Pharmaceuticals

INNOCAN PHARMA Corp

Calgary, A0 · CIK 0001889791

Offering snapshot reported Oct 26, 2021 · SEC filing

Reported sold
$6.61M
Offering amount: $6.61M
Investors reported
8
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Oct 13, 2021
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Oct 26, 2021Initial$6,610,515No comparison8SEC filing

Offering details

Securities
Equity, Option to acquire
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$446K
Finders' fees
$0
Form D file number
021-418536
Based on the exchange rate of Bank of Canada for October 13, 2021. The amount in Canadian dollars was of 8,227,150.
Based on the exchange rate of Bank of Canada for October 13, 2021. The amount in Canadian dollars was of $555,575.

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
A.G.P. Alliance Global Partners8361

Source: Form D, filed Oct 26, 2021. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Iris Bincovich Director, Executive
Peter Bloch Director
Ralph Bossino Director
Yoram Drucker Director, Executive
Eyal Flom Director
Nelson Halpen Executive
Joshua A. Lintern Director
Ron Mayron Director, Executive

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
1015, 926 5 Avenue Sw
Calgary, A0, T2P 0N7